Log in to save to my catalogue

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomis...

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomis...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1273259435

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute heart failure. The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would...

Alternative Titles

Full title

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1273259435

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1273259435

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(12)61855-8

How to access this item